ACADIA Pharmaceuticals Inc. (DR6.F)
| Previous close | 15.81 |
| Open | 14.24 |
| Bid | 14.22 x 30000 |
| Ask | 14.35 x 30000 |
| Day's range | 14.24 - 14.24 |
| 52-week range | 14.24 - 29.40 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 2.354B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | ∞ |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO, May 09, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:
- Business Wire
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
SAN DIEGO, May 08, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
- Business Wire
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
